Kolon TissueGene tumbles on mislabeling revelation for cell therapy Invossa

Kolon TissueGene suspended enrollment in a U.S. Phase III trial of Invossa after finding that the osteoarthritis therapy's TGFB1-expressing component is

Read the full 216 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE